Therapeutic use of the HPV vaccine in
recurrent respiratory papillomatosis: A case report.
A prospective study of the incidence of juvenile-onset
recurrent respiratory papillomatosis after implementation of a national HPV vaccination program.
The RRP task force national registry for juvenile onset
recurrent respiratory papillomatosis (JO-RRP); initial results from a three year study.
Imayoshi et al., "Rare case of malignant transformation of
recurrent respiratory papillomatosis associated with human papillomavirus type 6 infection and p53 overexpression," Springer Plus, vol.
In this prospective study using data from the Australian Paediatric Surveillance Unit, researchers examined the incidence of juvenile-onset
recurrent respiratory papillomatosis from October 2011 to December 2015, set against the background of the introduction of Australia's national HPV vaccination program between 2007 and 2009 (J Infect Dis.
Treatment of
recurrent respiratory papillomatosis with human leukocyte interferon.
Malignant transformation of a highly aggressive human papillomavirus type 11-associated
recurrent respiratory papillomatosis. Am J Otolaryngol.
But if the vaccine's benefits in reducing vulvar and vaginal cancers, genital warts, anal cancer,
recurrent respiratory papillomatosis, oropharyngeal cancer, and penile cancer are also con sidered, the cost per QALY when vaccinating males drops to $24,400442,700.
Anesthetic management for laser excision of
recurrent respiratory papillomatosis in a third trimester parturient.
The compound is also used as an adjuvant therapy for
recurrent respiratory papillomatosis, a disease of the head and neck caused by human papillomavirus (usually types 6 and 11) that causes growths in the airway that can lead to death.
However, the quadrivalent vaccine (Gardasil), offers additional protection against HPV types 6 and 11, which cause over 90% of genital warts, 30% of minor cervical abnormalities, and almost all cases of
recurrent respiratory papillomatosis (warts on the vocal cords).
